Search Results

Treatment Update: Myelodysplastic Syndromes (MDS)

Topics Covered We invite you to learn more about: Myelodysplastic syndromes subtypes Current and emerging treatments Side-effects management Th…

Targeting Plek2 for the treatment of myeloproliferative neoplasms

Current therapy for MPNs remains suboptimal with ongoing risks for thrombosis. Newer drug such as JAK inhibitor has toxicity and is not curative. New …

Development of therapeutic strategy for the treatment of MDS

TP53 mutations are present in 10% of MDS cases and are associated with reduced survival and poor prognosis. However, the effect(s) of TP53 mutations o…

A novel BAFF CAR-T for treatment of HCL

Despite the success of Chimeric antigen receptor T cell (CAR-T) immunotherapies, disease relapse occurs in a majority of patients. We have developed a…

Exploring New Approaches in AML Treatment

Topics Covered We invite you to learn more about: Emerging therapies for acute myeloid leukemia (AML) Precision medicine for AML Managing side-…

CLL: Navigating Treatment with BTK Inhibitors

PresentationClick Here

NHL & CLL Diagnosis and Treatment Update

Topics Covered Signs and symptoms of indolent and aggressive NHL subtypes & CLL Diagnosis and treatment planning for indolent and aggressive NHL…

AML and Children: Understanding Diagnosis and Treatment

Dr. Katherine Tarlock, a pediatric hematology expert from Seattle Children’s Hospital briefly discusses AML and its prevalence in children. She will d…

What Are the Current Treatment Options for AML?

Topics Covered We invite you to learn more about: An overview of current treatment options, including chemotherapy, targeted therapy and treatment…

Treatment Advances for Myelodysplastic Syndromes (MDS)

Topics Covered We invite you to learn more about: Treatments for myelodysplastic syndromes Managing side effects Discussing quality-of-life issu…

The Future of Myeloma Treatment: What’s Next?

Long-term and late effects of blood cancer treatment

Long-term effects can linger for months or years after therapy. Heart disease and other cancers can appear years after treatment.

KT1, a novel NK trispecific antibody for the treatment of AML and MDS

New treatments for AML and MDS are urgently needed. We have developed and performed preliminary testing of a novel, patent-protected, trispecific NK c…

Beyond azacitidine: investigating new therapeutic strategies for the treatment of MDS

This proposal aims to understand the molecular mechanisms underlying response to AZA therapy in MDS, as a basis for developing more effective therapie…

FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA

The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one…

FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse

The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectabl…

Translating molecular profiles into treatment approaches to target disparities in lymphoma

Although many patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is sig…

Schooling children and teens during blood cancer treatment

Virtual, inpatient, and homebound learning are available to help your child continue their education while undergoing treatment for blood cancer.

Choosing a pediatric blood cancer specialist or treatment center

After your child receives a blood cancer diagnosis, you will want to find a blood cancer specialist or choose a treatment center. Here’s how.

Making blood cancer treatment decisions for your child

Learn how to get a second opinion and what questions to ask your child's blood cancer care team before you decide on a treatment plan.

Making blood cancer treatment decisions for young adults

Learn how to get a second opinion and what questions to ask your blood cancer care team before you move forward with a treatment plan.

Treatment Advances For Slow-Growing Non-Hodgkin Lymphomas

Treatment Advances For Slow-Growing Non-Hodgkin Lymphomas

[Click here to enlarge.] Topics Covered We invite you to learn more about: The importance of knowing your non-Hodgkin lymphoma (NHL) subtype …

Managing blood cancer treatment side effects in young adults

Treatment side effects may last well after treatment is completed or may be permanent. 

Managing blood cancer treatment side effects in children and teens

Treatment side effects may last well after treatment is completed or may be permanent.